

The Boolean Kinetics of Signal Transduction: Supplementary Material

Equations of the LAC_SIM model of the *E.coli* Lac operon (Figure 1):

$$v1 = Vm1 / (1 + (RPf/Ki1) ^ n1)$$

where RPf is free (unbound) concentration of lac repressor

$$v2 = \beta\text{-Gal} * k2$$

where $\beta\text{-Gal}$ is concentration of β -galactosidase

$$v3 = Vm3 * \text{lactoseC} / (\text{lactoseC} + Km3)$$

where lactoseC is cellular lactose concentration; $Vm3 = \beta\text{-Gal} * TO3$

$$v4 = \text{lactoseE} * k4$$

where lactoseE is extracellular lactose concentration

$$v5 = \text{permease} * k5$$

where permease is concentration of galactoside permease

$$v6 = Vm6 * \text{lactoseE} / (\text{lactoseE} + Km6) / (1 + I/Ki6)$$

where $Vm6 = \text{permease} * TO6$ and I is an inhibitor of facilitated transport.

$$v7 = \text{lactoseC} * k7$$

$k2, k4, k5$ and $k7$ are first-order rate constants for their respective reactions. $Vm1, Vm3$ and $Vm6$ are maximal velocities; $Vm1$ is a constant, and $Vm3$ and $Vm6$ are the product of the respective enzyme concentrations and their turnover numbers, $TO3$ and $TO6$, respectively; $Km3$ and $Km6$ are Michaelis constants; $Ki1$ and $Ki6$ are noncompetitive inhibition constants; $n1$ and $n3$ are Hill constants.

Then lactoseE is constant

$$d[\text{lactoseC}]/dt = v4 + v6 - v3 - v7$$

$$d[\beta\text{-Gal}]/dt = v1 - v2$$

$$d[\text{permease}]/dt = v1 - v5$$

$$RPf = RPt / (1 + (\text{lactoseC}/Ki3)^{n3})$$

where RPt is total (free + alloactose-bound) concentration of lac repressor.

Parameter values used for the simulations discussed in the main text were: $k2=1.0; k4=0.05; k5=4.5; k7=0.05; Vm1=100; TO3=0.167; TO6=0.98; Km3=0.2; Km6=0.05; Ki1=1.0$.

Equations of the MAPK_SIM model of the human MAPK signalling pathway (see figure 4):

$$v1 = Vm1 * cfos / (cfos + Km1) / (1 + cyclinD/Ki1)$$

$$v2 = cyclinD * k2$$

$$v3 = Vm3 * (\text{ras}/Km3)^{n3} / (1 + (\text{ras}/Km3)^{n3})$$

where ras indicates the ras-GTP complex.

$$v4 = Vm4 * \text{EGF}/Km4 / (1 + \text{EGF}/Km4) / (1 + \text{spr}/Ki4) / (1 + I4/Ki4)$$

where spr is the sprouty protein [25], and I4 is an inhibitor of the EGF receptor tyrosine kinase, e.g. erlotinib [26].

$$v5 = Vm5 * \text{Grb2}/Km5 / (1 + \text{Grb2}/Km5)$$

$$v6 = \text{Grb2} * k6$$

$$v7 = Vm7 * \text{MEKP}/Km7 / (1 + \text{MEKP}/Km7) / (1 + \text{spr}/Ki7)$$

where MEKP is the active, phosphorylated form of MEK.

$$v8 = \text{ras} * k8$$

$$v9 = Vm9 * \text{raf}/Km9 / (1 + \text{raf}/Km9) / (1 + \text{ERKP}/Ki9) / (1 + I9/Ki9)$$

where ERKP is the phosphorylated form of ERK and I9 is a raf kinase inhibitor, e.g. sorafenib [27].

$$v10 = Vm10 * \text{MEKP}/Km10 / (1 + \text{MEKP}/Km10)$$

$$v_{11} = ERKP * k_{11}$$

k_2 , k_6 , k_8 and k_{11} are first-order rate constants for their respective reactions. V_{m1} , V_{m3} , V_{m4} , V_{m5} , V_{m7} , V_{m9} and V_{m10} are maximal velocities; K_{m1} , K_{m3} , K_{m4} , K_{m5} , K_{m7} , K_{m9} and K_{m10} are Michaelis constants; K_{i1} , K_{i4} , K_{i7} , K_{i8} , K_{i9} and K_{inc} are noncompetitive inhibition constants; n_3 is a Hill constant.

Then

$$d[Grb2]/dt = v_4 - v_6$$

$$d[ras]/dt = v_5 + v_{21} - v_8; \text{ note: } v_{21} \text{ is a cross-talk signal from the PI3K pathway, discussed below.}$$

$$d[raf]/dt = v_3 - v_9$$

$$d[MEKP]/dt = v_9 - v_{10}$$

$$d[ERKP]/dt = v_{10} - v_7 - v_{11}$$

$$d[cfos]/dt = v_7 - v_1$$

k_2 , k_6 , k_8 and k_{11} are first-order rate constants for their respective reactions. V_{m1} , V_{m3} , V_{m4} , V_{m5} , V_{m7} , V_{m9} and V_{m10} are maximal velocities; K_{m1} , K_{m3} , K_{m4} , K_{m5} , K_{m7} , K_{m9} and K_{m10} are Michaelis constants; K_{i1} , K_{i4} , K_{i7} and K_{i9} are noncompetitive inhibition constants; n_3 is a Hill constant.

$k_2=1.6$; $k_6=.05$; $k_8=.028$; $k_{11}=.02$; $V_{m1}=19.4$; $V_{m3}=10$; $V_{m4}=.33$; $V_{m5}=50$; $V_{m7}=20$; $V_{m9}=10$; $V_{m10}=20$; $K_{m1}=1$; $K_{m3}=30$; $K_{m4}=1$; $K_{m5}=3.5$; $K_{m7}=10$; $K_{m9}=2$; $K_{m10}=1$; $K_{i1}=10$; $K_{i3}=1$; $k_{i4}=1$; $K_{i5}=1$; $K_{i7}=1$; $K_{i9}=400$; $K_{i10}=1$; $n_3=4$.

Equations of the Akt_SIM model of the human Akt (PI3K) signalling pathway (Figure 7):

$$v_{12} = V_{m12} * PDGF/K_{m12} / (1 + PDGF/K_{m12})$$

$$v_{13} = PI3K * k_{13}$$

$$v_{14} = V_{m14} * PI3K/K_{m14} / (1 + PI3K/K_{m14}) / (1 + I_{14}/K_{i14})$$

where I_{14} is an inhibitor of PI3 kinase, e.g. LY294002 [28].

$$v_{15} = V_{m15} * Akt/K_{m15} / (1 + Akt/K_{m15})$$

$$v_{16} = V_{m16} * mTOR/K_{m16} / (1 + mTOR/K_{m16})$$

$$v_{17} = eIF4E * k_{17}$$

$$v_{18} = V_{m18} * mTOR/K_{m18} / (1 + mTOR/K_{m18})$$

$$v_{19} = p70S6K * k_{19}$$

$$v_{20} = V_{m20} * eIF4E/K_{a20} / (1 + eIF4E/K_{a20}) * p70S6K/K_{b20} / (1 + p70S6K/K_{b20})$$

$$v_{21} = PI3K * k_{21}$$

$$v_{22} = ras * k_{22}$$

k_{13} , k_{17} , k_{19} , k_{21} and k_{22} are first-order rate constants for their respective reactions. V_{m12} , V_{m14} , V_{m15} , V_{m16} , V_{m18} and V_{m20} are maximal velocities; K_{m12} , K_{m14} , K_{m15} , K_{m16} and K_{m18} are Michaelis constants; K_{a20} and K_{b20} are dissociation constants for binding of eIF4E and p70S6K respectively; K_{i14} is a noncompetitive inhibition constant.

Then

$$d[PI3K] = v_{12} + v_{22} - v_{13}$$

$$d[Akt] = v_{14} - v_{15}$$

$$d[mTOR] = v_{15} - v_{16} - v_{18}$$

$$d[eIF4E] = v_{16} - v_{17}$$

$$d[p70S6K] = v_{18} - v_{19}$$

Parameter values used for the simulations used in the main text were: $k_{13}=.05$; $k_{17}=.2$; $k_{19}=.1$; $k_{21}=.01$; $k_{22}=.01$; $V_{m12}=.66$; $V_{m14}=2$; $V_{m15}=4$; $V_{m16}=5$; $V_{m18}=3$; $V_{m20}=6$; $K_{m12}=1$; $k_{m14}=5$; $K_{m15}=5$; $K_{m16}=5$; $K_{m18}=4$; $K_{m20}=1$.

Copyright: ©2017 Jackson RC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.